Consider ENBREL “NOW” When Symptoms Are Moderate to Severe

ENBREL is indicated for reducing signs and symptoms of RA, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.¹

The risk of progressive structural damage is high in patients with moderate to severe RA. Structural damage may still be occurring in your RA patients despite clinical improvements with MTX alone. Adding ENBREL to MTX early in moderate to severe RA has been proven more efficacious—clinically, structurally, and functionally—than MTX alone.

ENBREL has proven results

In clinical studies, patients on ENBREL achieved efficacy in moderate to severe RA across 3 measures^1,2:

Clinical Efficacy

Reduction in clinical signs and symptoms

Structural Efficacy

Inhibition of progression of structural damage

Functional Efficacy

Improvement in physical function

ENBREL has long-term experience

ENBREL has extensive clinical experience as the first tumor necrosis factor (TNF) inhibitor approved in the United States in each of its indications. The efficacy and safety of ENBREL have been tested in clinical studies over 18 years.

In 1998, ENBREL was the first TNF inhibitor approved for moderate to severe RA in DMARD*-refractory patients
ENBREL has been evaluated in RA clinical studies over the past 18 years²^†
ENBREL has 12+ years of postmarketing experience and more than 2.8 million patient-years of postmarketing experience worldwide across indications²^‡
ENBREL has 10+ years of continuous safety data in RA clinical trials²

^*DMARD = disease-modifying antirheumatic drug.

^†Initial clinical research in RA patients began in 1993.

^‡Based on estimated number of patient-years from 1998 through September 2010. Estimated number of patient-years is calculated based on the number of ENBREL units distributed and an estimated average dose.

Learn more about the efficacy of ENBREL in moderate to severe RA:

Reduce Signs and Symptoms
Inhibit Progression of Structural Damage
Improve Function

Reduce Signs and Symptoms Dosing and Administration

Important Safety Information Prescribing Information Medication Guide

Indications

Moderate to Severe Rheumatoid Arthritis Supportive Data

View in-depth ENBREL efficacy data from the COMET trial

Explore 3 measures of efficacy in moderate to severe RA with COMET Interactive.

Take a deeper look

Consider ENBREL “NOW” to help inhibit progression of structural damage

Watch a brief video about the interrelated processes of inflammatory disease activity and the development of structural damage.

Play Video

Before ENBREL it was hard for Debra to do several things she took for granted.

Debra C., Clinical trial patient since 1997; ENBREL approved for moderate to severe RA in 1998

Prescribing Information Medication Guide

Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

Continue

If you are a resident of a country other than the United States, please visit the Pfizer website and the Amgen website to find information about our offices around the globe.